Article: How to measure HCP levels in new expression systems

22 June 2020

The increasing prevalence of new expression systems in biomanufacturing, new modalities in biotherapeutics, and new analytical technologies such as LC-MS/MS, is likely to lead regulators towards the requirement for more HCP data from biopharma manufacturers.

This article addresses the issues and proposes a new way of securing a comprehensive, 4-dimensional digital record of HCP data for potential future requirement by regulatory bodies.

Request a copy of the article here >>